Linked Life Data

9736542

Source:http://linkedlifedata.com/resource/pubmed/id/9736542

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9736542rdf:typepubmed:Citationlld:pubmed
pubmed-article:9736542lifeskim:mentionsumls-concept:C0206178lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C0521026lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C0070895lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C0286079lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C0332154lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C0021149lld:lifeskim
pubmed-article:9736542lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9736542pubmed:issue9lld:pubmed
pubmed-article:9736542pubmed:dateCreated1998-10-22lld:pubmed
pubmed-article:9736542pubmed:abstractTextCytomegalovirus (CMV) retinitis is a common opportunistic infection in patients with AIDS. With long-term therapy for CMV retinitis, resistant CMV may develop. In a prospective study of 122 patients with CMV retinitis, 2.4 and 0.8% of patients had foscarnet-resistant blood culture isolates (50% inhibitory concentration [IC50], >400 microM) and urine culture isolates, respectively, at diagnosis of CMV retinitis prior to treatment, whereas 4.1 and 6.6% had cidofovir-resistant (IC50, >2 microM) blood and urine culture isolates, respectively. Patients were treated according to best medical judgement. Of 44 foscarnet-treated patients, 26% had a resistant blood or urine culture isolate by 6 months of treatment and 37% had a resistant isolate by 9 months; of 13 cidofovir-treated patients, 29% had a resistant blood or urine culture isolate by 3 months of therapy. The probabilities of developing foscarnet resistance while on foscarnet and developing cidofovir resistance while on cidofovir were not significantly different from that for developing ganciclovir resistance while on ganciclovir (odds ratios, 1.87 [P = 0.19] and 2.28 [P = 0.15], respectively).lld:pubmed
pubmed-article:9736542pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:languageenglld:pubmed
pubmed-article:9736542pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:citationSubsetIMlld:pubmed
pubmed-article:9736542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736542pubmed:statusMEDLINElld:pubmed
pubmed-article:9736542pubmed:monthSeplld:pubmed
pubmed-article:9736542pubmed:issn0066-4804lld:pubmed
pubmed-article:9736542pubmed:authorpubmed-author:FormanMMlld:pubmed
pubmed-article:9736542pubmed:authorpubmed-author:DunnJ PJPlld:pubmed
pubmed-article:9736542pubmed:authorpubmed-author:EngelMMlld:pubmed
pubmed-article:9736542pubmed:authorpubmed-author:JabsD ADAlld:pubmed
pubmed-article:9736542pubmed:issnTypePrintlld:pubmed
pubmed-article:9736542pubmed:volume42lld:pubmed
pubmed-article:9736542pubmed:ownerNLMlld:pubmed
pubmed-article:9736542pubmed:authorsCompleteYlld:pubmed
pubmed-article:9736542pubmed:pagination2240-4lld:pubmed
pubmed-article:9736542pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:meshHeadingpubmed-meshheading:9736542-...lld:pubmed
pubmed-article:9736542pubmed:year1998lld:pubmed
pubmed-article:9736542pubmed:articleTitleIncidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.lld:pubmed
pubmed-article:9736542pubmed:affiliationDepartments of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. dajabs@welchlink.welch.jhu.edulld:pubmed
pubmed-article:9736542pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9736542pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9736542pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736542lld:pubmed